China's medical products administrator approved Fosun Pharmaceutical (HKG:2196, SHA:600196) subsidiary Fosun Pharma (Xuzhou)'s drug registration for venlafaxine hydrochloride sustained-release tablets.
The drug is indicated for depression, including depression with anxiety, and general anxiety disorder, according to a Thursday filing with the Hong Kong Exchange.
Shares rose 1% in Hong Kong during Friday's trading.
Price (HKD): $13.98, Change: $+0.16, Percent Change: +1.16%